Studies evaluating the effects of previous chemotherapy on stem-cell yield and hematological recovery after autologous peripheral-blood progenitor-cell transplantation (PBPCT) have shown conflicting results. We have retrospectively analyzed 103 consecutive lymphoma patients treated with the BEAM regimen and autologous PBPCT. The impact of the different chemotherapeutic drugs (cumulative doses) on stem-cell yield and transplant-related toxicity was investigated. Highly significant differences in platelet recovery (420 Â 10 9 /l) were observed between patients receiving less or more than 750 mg/m 2 of etoposide before transplant (15 vs 29 days, P ¼ 0.001), and between patients receiving less or more than 1.2 Â 10 6 /kg CD34 þ cells (27 vs 14 days, Po0.001). Differences in neutrophil engraftment between groups were not clinically significant. Pre-transplant cumulative doses of etoposide 4750 mg/m 2 were associated with low CD34 þ cell collections on multivariate analysis. The actuarial incidence of transplant-related mortality (TRM) was 14% at 5 years. Pre-transplant cumulative doses of etoposide 4350 mg/m 2 and previous administration of procarbazine were found to be independent prognostic factors for TRM.
BEAM; CD34 þ cells
High-dose chemotherapy supported by autologous stemcell transplantation (ASCT) is a successful treatment for patients with relapsing or resistant non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD). [1] [2] [3] Mobilized peripheral-blood progenitor-cells (PBPC) have largely replaced autologous bone marrow (BM) as the stem-cell source, mainly due to the noninvasive collection technique and a faster engraftment after PBPC transplantation. 4 Prior chemotherapy, number of CD34 þ cells infused, and administration of hematopoietic growth factors influence hematologic recovery. [5] [6] [7] [8] [9] [10] [11] [12] Several studies using animal models have shown that cytotoxic agents such as busulfan, BCNU, melphalan, or platinum derivates reduce the repopulating capacity of BM, whereas others have not demonstrated such an association. [13] [14] [15] [16] Clinical trials evaluating the impact of previous chemotherapy on progenitor-cell yield and engraftment have shown conflicting results. Previous studies have generally been limited to estimations on the number of regimens or cycles of chemotherapy to which a patient has been exposed, 6, 11, 12, 17, 18 or the effect of one specific regimen, 6, [19] [20] [21] but to our knowledge there has been no analysis comparing the effects of cumulative doses of the different chemotherapeutic drugs on progenitor-cell yield and hematological recovery. This is of particular interest in lymphoma patients since most of them receive salvage chemotherapy including agents that may affect progenitorcells prior to apheresis and transplantation.
In this study, we have analyzed 103 lymphoma patients, homogeneously treated with the BEAM regimen and autologous PBPC transplantation. The main objective was to investigate the impact of the different chemotherapeutic drugs (individual cumulative doses) received before transplant on stem-cell yield and hematological recovery.
Patients and methods

Patients and prior chemotherapy
A total of 103 consecutive patients diagnosed with lymphoma who received BEAM conditioning and PBPC transplantation at our institution between April 1991 and June 1999 were included in the study. Patient characteristics are summarized in Table 1 . The doses and number of cycles of the different drugs to which patients had been exposed before transplant are summarized in Table 2 . Written informed consent using institutionally approved forms was obtained from all patients.
Progenitor-cell collection
Mobilization of PBPC was performed in 85 patients using G-CSF administered in the steady-state phase, after recovery from the last cycle of chemotherapy, at a dose of 5-10 mg/kg/day. Nine patients received 2 g/m 2 cyclophosphamide in addition to G-CSF. In the remaining nine patients, PBSC collection was performed at the time of recovery of the last cycle of salvage chemotherapy (Mini-BEAM, six patients; ESHAP, two patients; CYM, one patient), after stimulation with G-CSF.
Stem-cell aphereses were performed using a continuous flow cell separator, CS 3000 Plus, with a small volume collection chamber (50 ml) (Baxter). The target dose to stop apheresis used at our center until 1998 was 41 Â 10 /kg (range: 0.06-36.4). Following collection, cells were resuspended in 10% DMSO with autologous plasma and frozen in a controlled rate freezer at À11C/min and stored in liquid nitrogen at À1961C.
CD34 measurement
The absolute number of CD34 þ cells was measured in erythrocyte-lysed PB samples as well as in the leukapheresis product. Cells were stained with an anti-CD34 monoclonal antibody (antiHPCA-2) conjugated with PE and analyzed by flow cytometry (FACScan, Becton Dickinson, San Jose, CA, USA) as previously described, 8,9,22 using a two-step acquisition procedure. In the second acquisition step, a total of 300 000 events were acquired to assure a low coefficient of variation for the measurement. A side scatter/ CD34-PE live gate was performed in which only cells with high intensity of PE fluorescence were selected. -176 ), respectively. G-CSF (5 mg/kg/day) was administered to 96 patients (93%) after transplant, from day þ 6 to hematological recovery (neutrophil count 41 Â 10 9 /l for three consecutive days).
High-dose chemotherapy and progenitor-cell reinfusion
Toxicity
Neutrophil recovery was defined as the first of three consecutive days with an ANC greater than 0.5. and 1 Â 10 9 /l. Platelet recovery was defined as the first of three consecutive days with an unsupported platelet count greater than 20 Â 10 9 /l. Engraftment was considered stable when patients reached normal counts in PB (Hb 412 g/ dl þ leucocytes 44 Â 10 9 /l þ granulocytes 41.5 Â 10 9 / l þ platelets 4100 Â 10 9 /l). For evaluation of long-term engraftment, patients who died due to transplant toxicity not related to graft failure or who developed progressive disease during the first year after transplantation were excluded.
Transplant-related mortality (TRM) was considered at any time if it was due to a recognized complication of the procedure. Early TRM was defined as death from any cause other than lymphoma occurring within 100 days after high-dose therapy.
Statistical analysis
The primary outcomes for analysis were progenitor-cell yield (number of CD34 þ cells collected) and hematological recovery after transplantation (days to reach an ANC 40.5 and 1 Â 10 9 /l, days to reach a platelet count 420 Â 10 9 /l, and days to reach normal counts in PB). The secondary outcomes for analysis were incidence of treatment-related myelodysplasia, and overall and early TRM rates. Differences in hematological recovery between groups according to the different covariates were analyzed by Kaplan-Meier and log-rank tests. A forward stepwise Cox proportional hazards regression model was used for multivariate analysis, including all variables with a P-value o0.1 in univariate analysis. Qualitative parameters were analyzed using w 2 test and multiple logistic regression. All P-values reported are two-sided and statistical significance is defined as a P-value less than 0.05. The statistical analyses were carried out with SPSS statistical software (SPSS, Inc., Chicago, IL, USA).
Univariate and multivariate analyses were used to evaluate the following characteristics: type of lymphoma, sex, age at transplantation, extranodal and BM involvement at diagnosis and at transplantation, disease status at transplant, previous chemotherapy, previous radiotherapy, mobilization protocol (GCS-F alone vs cyclophosphamide plus G-CSF vs chemotherapy regimen plus G-CSF), conditioning regimen (standard BEAM vs BEAM with escalated etoposide dose), use of G-CSF after transplantation, and number of MNC, CD34 þ cells and CFU-GM infused. For assessment of previous chemotherapy, the cumulative dose of each individual agent was estimated. The number of chemotherapy lines (1 vs 2 vs X3) and the type of salvage treatment, MiniBEAM (yes vs no) and ESHAP (yes vs no), were also analyzed. Quantitative variables (age, dose of each chemotherapeutic drug, and number of MNC, CD34
þ cells and CFU-GM infused) were transformed into binary variables using the quartiles as cutoff values.
Results
Hematological recovery
Three patients died before engraftment due to transplant toxicity not related to graft failure. These patients were not evaluated for hematological recovery. Among evaluable patients, all but one achieved engraftment. One patient who received 0.5 Â 10 6 /kg CD34 þ cells had a primary graft failure and died from hemorrhage. A total of 75 patients were evaluable for assessment of long-term hematological recovery, and 65 (87%) of them achieved normal blood counts. One patient who received 1.9 Â 10 6 /kg CD34 þ cells suffered a secondary loss of engraftment of unknown origin.
The results of the univariate and multivariate analysis of variables affecting hematological recovery are shown in Table 3 . Factors influencing neutrophil recovery to 40.5 Â 10 9 /l were the same as those influencing neutrophil recovery to 41 Â 10 9 /l. As shown in the table, differences in neutrophil engraftment between groups according to the different covariates were not clinically important. In contrast, highly significant differences in platelet recovery (420 Â 10 Doses are expressed in mg/m 2 or units (bleomycin) as appropriate. a Number of patients exposed to the drug. Only a minority of patients were exposed to ifosfamide (n ¼ 3), 6-thioguanine (n ¼ 1), fludarabine (n ¼ 3), or hydroxyurea (n ¼ 1).
CFU-GM infused significantly influenced platelet engraftment (Table 3) . With respect to long-term engraftment, the number of CD34 þ cells and CFU-GM infused were the single factors affecting the complete hematological reconstitution, as shown in Table 3 . In multivariate analysis, only the number of CD34 þ cells infused (o1.2 Â 10 6 /kg) retained statistical significance. Our analysis did not identify any single chemotherapeutic drug or regimen that significantly affected long-term engraftment.
Progenitor-cell collection
The results of the univariate and multivariate analysis of variables affecting CD34 þ cell yield are shown in Table 4 . Factors significantly associated with a low CD34 þ cell collection (o1.2 Â 10 6 /kg, the cutoff value [quartile 1] with the most significant impact on engraftment) were extranodal involvement at diagnosis, and chemotherapy received prior to apheresis (number of lines 42, and cumulative doses of etoposide 4750 mg/m 2 ). In multivariate analysis, Results are expressed as the median of days (range). HR ¼ hazard ratio. (Table 4) .
Secondary myelodysplastic syndrome
Three patients (2.91%; 5-year cumulative probability of 4.24%; 95% confidence interval (CI): 0-8.8%) developed a secondary myelodysplastic syndrome (MDS) with cytogenetic abnormalities that were not detected prior to transplant (deletions of chromosomes 5, 7, and 15 in one patient, trisomy 13 in one patient, and t(1;7) in another patient), at 14, 27, and 39 months after transplantation, respectively. These three patients died, one due to the MDS, and two from complications due to subsequent treatments (intensive chemotherapy and allogeneic transplantation, respectively). Factors that increased the incidence of secondary MDS were pre-transplant cumulative doses of nitrogen mustard 424 mg/m 2 (9.1 vs 1.3%, P ¼ 0.054), and the use of cyclophosphamide instead of G-CSF alone as a mobilization protocol (11.8 vs 0%, P ¼ 0.012).
Transplant-related mortality
The results of the univariate and multivariate analysis of variables affecting TRM are shown in Table 5 . Six patients (5.82%; 95% CI: 2.2-12.2%) experienced treatment-related mortality within the first 100 days following 
cells). HR ¼ hazard ratio.
Etoposide in autologous lymphoma transplantation A Martín et al transplantation. The causes were interstitial pneumonitis/ adult respiratory distress syndrome in two patients, infectious episodes in two patients (fungal infection), and multiorgan failure in another two patients. Multivariate analysis identified pre-transplant cumulative doses of vincristine416 mg/m 2 and previous administration of radiotherapy as significant prognostic factors for early TRM (Table 5) .
Another six patients (5.82% of the series) died beyond the first 100 days after transplantation from transplant-related causes: secondary MDS in three patients, other secondary malignancies in one patient (melanoma), infectious episode in one patient (viral infection), and hemorrhage due to a primary graft failure in another patient. The overall TRM was 13.87% at 5 years by Kaplan-Meier analysis (95% CI: 6.2-21.3%). In multivariate analysis, pre-transplant cumulative doses of etoposide 4350 mg/m 2 , and previous administration of procarbazine significantly increased the risk of TRM (Table 5) . 
Discussion
High-dose chemotherapy followed by ASCT is widely used in relapsing or resistant NHL or HD patients. A major problem is that these patients have usually received two or more chemotherapy regimens, which may compromise the procedure. Prior exposure to specific cytotoxic agents has been associated with a reduced progenitor-cell yield and a significant delay in hematological recovery after autologous transplantation. 6, 7, 11, 23, 24 However, studies evaluating the effects of previous chemotherapy have shown conflicting results. Thus, in some cases it has been reported that prior chemotherapy hampers both stem-cell collection and engraftment, 6, 7 while others have shown that it influences the CD34 counts but not hematopoietic recovery, 17, 25 and finally, others have been unable to detect such detrimental effects. 26, 27 Our results show that prior administration of high doses of etoposide (4750 mg/m 2 ) was the most important factor affecting CD34
þ cell yield and platelet recovery. This is an unexpected finding, since although several cytotoxic agents, such as busulfan, melphalan, carmustine, platinum derivates, nitrogen mustard, or chlorambucil have been associated with stem-cell damage; 6, 7, [13] [14] [15] [16] [28] [29] [30] etoposide is not usually included among them. This is clinically important, because etoposide-containing regimens are often used as salvage therapy for lymphomas. Another interesting finding was that, according to multivariate analysis, pre-transplant cumulative doses of etoposide 4750 mg/m 2 adversely affected platelet engraftment independent of CD34 þ cell dose infused. This result suggests that the delay in platelet engraftment can not only be explained by a reduction in stem-cell yield, and, as suggested by Gandhi et al, 23 it could also be attributed to the damage in bone marrow microenvironment induced by some drugs. Alternatively, etoposide may have a more direct cytotoxic effect on megakaryocyte precursors than on other progenitor cells.
Our analysis failed to identify any single chemotherapeutic drug that significantly affected long-term engraftment. As pointed out by Dreger et al, 6 one possible explanation is that chemotherapy affects preferentially committed rather than immature progenitor cells.
In our study, in accordance with previous reports, [8] [9] [10] 31 we found that the CD34 þ cell dose infused directly influenced the speed of neutrophil and platelet engraftment. In addition, it was the single factor affecting long-term engraftment. Our results suggest that a minimum of 1.2 Â 10 6 /kg CD34 þ cells should be infused to obtain a rapid and permanent engraftment. It is important to mention that usually higher values of CD34 þ cell dose have been recommended by other groups. 5, 10 Discrepancies are probably due to the method employed for the analysis. It has become clear that CD34
þ flow cytometry methodology constitutes a potential source of bias when comparing engraftment data across studies. It should be pointed out that we have used a very sensitive and specific method in which 300 000 events were screened. The reproducibility of this method, and its ability to predict the speed of hematopoietic recovery, 8, 9 indicates that this is a reliable method for the assessment of progenitor-cells.
In accordance with Drake et al, 7 but in contrast to other studies, 6 ,17,25 we did not find prior radiotherapy to be a significant deleterious factor affecting stem-cell yield or hematological recovery. Interestingly, the presence of extranodal involvement was associated with low CD34 þ cell counts and a significant delay in neutrophil engraftment. One possible explanation is that patients with extranodal disease are frequently more heavily pretreated. In addition, BM infiltration is present in many of these patients, contributing to such detrimental effects. As far as the conditioning regimen is concerned, dose intensification of etoposide from 800 to 1600 mg/m 2 in BEAM regimen was not associated with greater toxicity, as previously reported by Mills et al.
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The early TRM observed in our series was 5.8%, a rate within the range reported by other recent studies. [33] [34] [35] [36] Late TRM occurred in six additional patients from our series (raw incidence of 5.8%), the most frequent causes being secondary MDS. As in other studies, [33] [34] [35] TRM was mainly associated with pre-transplant chemotherapy and radiotherapy treatment. We have specifically identified cumulative doses of vincristine 416 mg/m 2 and use of radiotherapy before transplant as independent prognostic factors for early TRM, and cumulative doses of etoposide 4350 mg/m 2 and previous administration of procarbazine as independent prognostic factors for overall TRM. Once again, prior etoposide was one of the most important factors affecting TRM. Interestingly, cumulative doses of etoposide influencing TRM (4350 mg/m 2 ) were lower than those influencing CD34 þ cell yield and engraftment (4750 mg/m 2 ), thus suggesting that etoposide increases TRM through its extrahematological toxicity. In addition, etoposide could damage the BM microenvironment and the immune system at lower doses than those needed to damage megakaryocyte precursors.
The 5-year actuarial incidence observed in our series was 4.24%, a rate similar to others reported in the literature. 34, 35, 37, 38 In our study, factors that increased the incidence of secondary MDS were pre-transplant cumulative doses of nitrogen mustard 424 mg/m 2 and the use of cyclophosphamide instead of G-CSF alone as the mobilization protocol. The association between prior extensive use of alkylating agents and increased risk of secondary MDS/ AML in lymphoma patients is well documented. 37, 38 In contrast to other studies, 34, 35, 37, 38 we have not found prior radiotherapy, prior etoposide, or older age to be significant factors increasing the risk of secondary MDS. With respect to cytogenetic abnormalities, complete or partial deletions of chromosomes 5 and/or 7, as occurred in one of our patients, have been reported in 90% of treatment-related myelodysplasia. 38 The remaining cytogenetic abnormalities found in our patients, that is, trisomy 13 and t(1;7), are more rarely described in secondary MDS/AML patients. [37] [38] [39] In conclusion, our results show that the type and intensity of pre-transplant chemotherapy affect progenitorcell yield, hematological recovery, and transplant-related toxicity. We found an independent association between high cumulative doses of etoposide and CD34 þ cell collection, platelet engraftment, and TRM. Cumulative doses of etoposide should be monitored in patients considered as candidates to receive an autologous PBPC transplantation, in order to avoid limiting doses that may compromise the procedure.
